John_Wick1234 Posted - 14 hours ago

$EW Ascending Triangle Breakout With Good Volume.

JordanLov3 Posted - 2 days ago

$EW

WallStreetBuyDip Posted - 2 days ago

$EW the ticker name lol who did this

KaaAABooOOM Posted - 2 days ago

$EW Action building up 👀

KaaAABooOOM Posted - 2 days ago

$EW Nice

StockConsultant Posted - 5 days ago

$EW Edwards Lifesciences stock, watch for a bull flag breakout above 74.85 with a good sized upside gap to fill at https://stockconsultant.com/?EW

wolf12631 Posted - 1 week ago

@fjsteven I am a genius, thx Just look at the $EW and the $BSX chart

ScalpMaster Posted - 1 week ago

Favs: $MSTR over 427, $META over 630! Also watching $EW and $VRDN higher as well...

larrdawg Posted - 1 week ago

@Dr_Stoxx $EW is worth a look, if it already hasn't popped up your radar. Looks ready to breakout and at least have a date with the 200 SMA. Thoughts?

11thestate Posted - 1 week ago

$EW stockholders filed a claim against Edwards Lifesciences for misleading them about the growth prospects of its TAVR platform. You can check if you are eligible and file for the payment here: https://11thestate.com/cases/edwards-lifesciences-investor-suit

kcphaeton Posted - 1 week ago

$EW amazing there aren’t more followers of Edwards.

30DeltaSpy Posted - 1 week ago

$EW 💃🏎️💨

IN0V8 Posted - 2 weeks ago

$EW 12/5 Leerink Partners raises target price to $77 from $74 RBC raises target price to $85 from $80 Stifel raises target price to $75 from $70 TD Cowen raises target price to $75 from $70 Truist Securities raises target price to $78 from $70 UBS raises target price to $78 from $75

kcphaeton Posted - 2 weeks ago

$EW hopefully over the next 12 months Edwards will climb back close to their all-time high in 2021. It would be great to see them hit their 52 week high of $96.12 by the end of the first quarter of 2025 all-time high Edwards Lifesciences stock closing price was 130.68 on December 30, 2021. The Edwards Lifesciences 52-week high stock price is 96.12, which is 34.7% above the current share price.

TheDonofStocks Posted - 2 weeks ago

$EW only room to run up from here Similar to $TSLA $NVDA $TGT

MaverikIT Posted - 2 weeks ago

@IsabellaDC @net0trader $EW +3.23 - guidance$

briefingcom Posted - 2 weeks ago

$EW: Edwards Lifesciences outlines growth strategy at Annual Investor Conference; reaffirms FY24 sales growth guidance; provides FY25 outlook https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20241204061335EW&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

11thestate Posted - 2 weeks ago

$EW stockholders filed a claim against Edwards Lifesciences for misleading them about the growth prospects of its TAVR platform. You can check if you are eligible and file for the payment here: https://11thestate.com/cases/edwards-lifesciences-investor-suit

DonCorleone77 Posted - 2 weeks ago

$EW Edwards Lifesciences sees FY25 adjusted EPS $2.40-$2.50, consensus $2.47 Sees FY25 revenue $5.6B-$6.0B, consensus $5.92B. Edwards Lifesciences enters 2025 in a strong position with major growth drivers in Transcatheter Aortic Valve Replacement, or TAVR, and Transcatheter Mitral and Tricuspid Therapies, or TMTT, the continued long-term performance of Surgical, and future opportunities with Structural Heart Failure and Aortic Regurgitation, or AR. Highlights of today's conference include: reaffirming original 2024 total company constant currency sales growth guidance of 8% to 10%; advancing broad portfolio of structural heart therapies with meaningful catalysts in 2025; TAVR growth reinforced by leading technology and EARLY TAVR; TMTT contribution accelerated by PASCAL, EVOQUE and SAPIEN M3; projecting 2025 constant currency sales growth of 8%-10%; TAVR sales of $4.1B-$4.4B; maintaining constant currency growth of 5%-7%, which assumes mid-year indication approval from EARLY TAVR; TMTT sales of $500M-$530M; constant currency growth of 50%-60%; increasing contribution from an expanding set of structural heart therapies in 2026 and beyond; targeting 10% average annual total company sales growth and double-digit EPS growth; mid-to-high single digit TAVR growth driven by EARLY TAVR and PROGRESS; TMTT increasing contribution to growth, reaching $2B by 2030; increasing contribution from new therapeutic areas including Structural Heart Failure and AR.

diamondoptionsinc Posted - 2 weeks ago

At 8:30am tomorrow: Edwards Lifesciences $EW investor meeting will begin 🔊

Estimize Posted - 3 weeks ago

Wall St is expecting 0.55 EPS for $EW Q4 [Reporting 01/30 AMC] http://www.estimize.com/intro/ew?chart=historical&metric_name=eps&utm_conten

Americanbulls Posted - 11/25/24

$EW apparently the bear pattern is not confirmed. Prices continue to rise. www.Americanbulls.com/SignalPage.aspx?lang=en&Ticker=EW

wolf12631 Posted - 11/25/24

$EW wifey just told me pace maker rates post Edward’s tavr at her hospital are off the charts

StockConsultant Posted - 11/25/24

$EW Edwards Lifesciences stock watch for a bottom breakout at https://stockconsultant.com/?EW

DonCorleone77 Posted - 11/25/24

$EW Edwards Lifesciences announces presentation of one-year SAPIEN 3 data Edwards Lifesciences announced one-year data highlighting the continued performance of its SAPIEN 3 Ultra RESILIA valve. The data were presented at PCR London Valves 2024 and simultaneously published in the Journal of the American College of Cardiology, or JACC: Cardiovascular Interventions. An analysis of data from more than 9,000 propensity-matched patients in the STS/ACC TVT Registry1 demonstrated that those who received Edwards' newest generation SAPIEN 3 Ultra RESILIA valve experienced outstanding one-year outcomes that continuously surpassed recipients of the earlier generation SAPIEN 3 and SAPIEN 3 Ultra valves. Patients receiving the SAPIEN 3 Ultra RESILIA valve experienced extremely low mortality, low rates of reintervention, larger effective orifice areas, lower echo-derived gradients across all valve sizes and no paravalvular leak in 84.4% of cases. Patients in the SAPIEN 3 Ultra RESILIA valve cohort, who had an average STS score of 3.6 and average age of 77, experienced meaningful quality of life benefits with a clinically significant average 31-point increase in KCCQ2 score and one-day length of hospital stay with 93% discharged to their homes.

traderhr Posted - 1 month ago

$EW is approaching a critical resistance within its horizontal consolidation zone, as highlighted in the chart. The narrowing symmetrical triangle pattern suggests potential for a breakout, which could signal a continuation of the upward trend if confirmed by increased volume. However, the possibility of a reversal remains if the price fails to sustain upward momentum and breaks below the ascending support trendline. Close attention to the Bollinger Bands and moving averages is essential for gauging the stock’s next move.

traderhr Posted - 1 month ago

Watch List: $TSLA $F $EW $PRU ... charts: https://www.traderhr.com/free-watch-list-for-nov-25th-2024/

larrdawg Posted - 1 month ago

$HG and $EW both on the verge of breakout. Especially EW and with a lot of room to run in the gap above. @Dr_Stoxx I know you have seen HG because you called it out several weeks ago. thoughts on $EW?

11thestate Posted - 1 month ago

$EW stockholders filed a claim against Edwards Lifesciences for misleading them about the growth prospects of its TAVR platform. You can check if you are eligible and file for the payment here: https://11thestate.com/cases/edwards-lifesciences-investor-suit

Estimize Posted - 1 month ago

Wall St is expecting 0.55 EPS for $EW Q4 [Reporting 01/30 AMC] http://www.estimize.com/intro/ew?chart=historical&metric_name=eps&utm_conten